About This Trial

Novel vaccine targeting conserved regions of coronaviruses to provide broad protection against future variants and related viruses.

Primary Endpoints

  • Cross-reactive antibody response
  • T-cell immunity breadth

Latest Update

February 2026

Phase 1 data demonstrated robust cross-neutralizing antibodies against SARS-CoV-1, SARS-CoV-2 variants, and MERS-CoV.

Lead Investigators

DK
Dr. Kathrin JansenFormer Head of Vaccine R&D